Investors

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

NASDAQ: MRNS
$ 6.86 +0.45 (7.02%)
Day High: 6.98
Day Low:  6.24
Volume:    959,444
2:33 PM ET
Jan 18, 2018

Delayed ~20 min., by eSignal.